News

03/10/2021

Using the new Johnson & Johnson Covid-19 vaccine to create equity and trust

If the newly-approved one dose Johnson & Johnson COVID-19 vaccine is offered in low-income and minority communities in preference to their Pfizer and Moderna counterparts, will it be perceived as another slight by these communities due to questions surrounding it’s effectiveness?  Public health and bioethics experts Drs. Ruth Karron and Ruth Faden discuss an option […]

02/12/2021

Booster shots, second-generation vaccines: COVID-19 vaccine makers rush to adapt to coronavirus variants

CIR Principal Investigator Dr. Durbin discusses plans for COVID-19 vaccine makers to combat new virus strains while continuing the roll out of currently licensed vaccines. 

02/11/2021

VERIFY: Here’s When Kids as Young as 12 Might be able to get a COVID-19 Vaccine

Some parents and children are wondering when the licensed COVID-19 vaccines will become available to children younger than 16 years old. NIAID Director Dr. Anthony Fauci and CIR Principal Investigator Dr. Kawsar Talaat are featured in this WUSA9 story which aims to verify the vaccine roll-out timeline for children in this age group.

01/08/2021

Dr. Ruth Karron Dispels Myths about COVID-19 Vaccines on The Brian Lehrer Show

Dr. Karron participated in the show’s third segment, called COVID-19 Vaccine 101, where she addressed topics like the nature of mRNA vaccines, vaccine hesitancy and myths including the unsubstantiated beliefs that COVID19 vaccines contain microchips and have the ability to change DNA.  

12/10/2020

What’s the Difference Between EUAs and Vaccine Licensure?

CIR Director Dr. Ruth Karron and faculty member Jessica Atwell answer Frequently Asked Questions regarding EUAs and COVID vaccine licensure.

11/18/2020

Johns Hopkins Center for Immunization Research to begin enrollment for CoVPN/AstraZeneca Phase 3 COVID-19 Vaccine Research Trial

The Center for Immunization Research at the Johns Hopkins Bloomberg School of Public Health is poised to begin enrolling study participants into a Phase 3 trial of the AstraZeneca COVID-19 vaccine AZD1222. The Center is one of approximately 80 sites in the United States that will evaluate this vaccine. About 30,000 participants will be enrolled in the study, which will evaluate the vaccine candidate for safety, efficacy, and immunogenicity against COVID-19. 

11/02/2020

CIR Participates in Licensed Flu Vaccine Clinic at Sacred Heart of Jesus Church

CIR faculty and staff in collaboration with Rite Aid and Notre Dame of Maryland Pharmacy gave back to the community at Friday’s Licensed Flu Vaccine Clinic at Sacred Heart of Jesus Church!

Translate »